Nivolumab plus ipilimumab vs nivolumab for previously treated patients with stage IV squamous cell lung cancer: The Lung-MAP S1400I phase 3 randomized clinical trial
JAMA — Gettinger SN, Redman MW, Bazhenova L, et al. | July 19, 2021
Researchers aimed at examining if the addition of ipilimumab to nivolumab results in improvement in survival of patients with advanced chemotherapy-pretreated immunotherapy-naive squamous cell lung cancer. They conducted the Lung Cancer Master Protocol (Lung-MAP) S1400I phase 3, open-label randomized clinical trial including 252 patients. Findings revealed no correlation of adding ipilimumab to nivolumab with improved survival in patients with advanced chemotherapy-pretreated squamous cell carcinoma. In patients with advanced non–small cell lung cancer, currently combination therapy with nivolumab and ipilimumab is only indicated as first-line therapy.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.